Thank you for subscribing!
Next Investors Jun 07, 2024
Our biotech Investment, Arovella Therapeutics (ASX: ALA) is developing an iNKT cell therapy platform to fight cancer, and is setting the stage for a Phase 1 clinical trial. Basically ALA’s treatment can find, identify and kill specific cancer cells, leaving other healthy cells unharmed,
Next Investors Mar 26, 2024
Our Investment ALA is trialling a technology to find, target and attack ONLY cancer cells, leaving the rest of the body healthy and unimpacted.
Next Investors Apr 21, 2022
Our biotech investment, Arovella Therapeutics (ASX:ALA), is one of only a handful of companies in the world working on an iNKT cell therapy for cancer.
Finfeed Archived Mar 18, 2020
OncoSil Medical Ltd’s (ASX: OSL) OncoSil™ device has reached a significant milestone, receiving Breakthrough Device Designation by the US FDA for the treatment of unresectable locally advanced pancreatic cancer.
Get expert stock analysis direct in your inbox
Next Investors Archived Jan 30, 2020
OncoSil Medical (ASX: OSL) has developed a first-in-class, truly innovative device that treats unresectable locally advanced pancreatic cancer — that is, tumours that can’t be surgically removed.
Finfeed Archived Dec 16, 2019
Australian Lions Childhood Cancer Research Foundation has announced it will provide $1.05 million of funding to the Telethon Kids Institute.
Finfeed Archived Nov 28, 2019
Shares in Prescient Therapeutics Limited (ASX:PTX) surged 50% on Wednesday after the clinical stage oncology company developing personalised medicine approaches to cancer released promising news.
Finfeed Archived Nov 18, 2019
With over 40 years’ experience in the healthcare diagnostic imaging industry, Imagion Biosystems (ASX:IBX) Board member Mike Harsh is one of the world’s most qualified people to speak about the evolution of diagnostics.
Finfeed Archived Nov 13, 2019
Imagion Biosystems Limited (ASX:IBX) has been issued patent #320872 from the Government of India Patent Office.
Next Investors Archived Nov 07, 2019
One ASX listed clinical stage oncology company is developing novel targeted cancer therapeutics for both humans and animals.
Finfeed Archived Nov 04, 2019
Clinical stage oncology company, PharmAust Ltd (ASX:PAA) has provided recruitment guidance for its anti-cancer trialling goals with treatment naïve B cell lymphoma.
Finfeed Archived Nov 01, 2019
Clinical-stage oncology company, PharmAust (ASX:PAA) has released its quarterly, highlighting the company's recent successes.
Next Investors Archived Oct 24, 2019
The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.
Finfeed Archived Oct 23, 2019
A US Department of Defense Grant has been awarded to renowned City of Hope researchers to fund research into gastric cancer, a disease that disproportionately affects US military service members, veterans, and their beneficiaries.
Finfeed Archived Oct 21, 2019
Imugene Limited (ASX:IMU) has provided a promising update on the preliminary clinical development plan (CDP) for the proposed exclusive license of the patents covering the CF33 oncolytic virus technology.
Next Investors Archived Oct 02, 2019
Emerging med-tech junior Genetic Technologies (ASX:GTG | NASDAQ:GENE) understands the importance of timely and precise targeting. Accessible predictive risk testing is where GTG lives and it has now signed a 3-year Collaboration Agreement with high profile US-based researcher Translational Genomics Research Institute (TGen).
Finfeed Archived Sep 23, 2019
Provider of world-leading genetic risk assessment test products Genetic Technologies Limited (ASX:GTG), has signed a 3-year Collaboration Agreement with TGen.
Finfeed Archived Sep 19, 2019
New antibodies for the key lead biomarker used in Rhythm Biosciences' (ASX: RHY) ColoSTAT® test can successfully differentiate between cancer and healthy samples, and the test has now been optimised.
Join Our Mailing List
